CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
==== With under-18s ==== In July 2025, the Government announced their intention to reduce the voting age to 16 before the next general election. Following this, some pollsters conducted polling including 16–17-year-olds, although the voting age has not yet been reduced by law.
By replacing the gene with a new version fused to a green fluorescent protein marker or similar, expression may be directly quantified in live cells. This is done by imaging using a fluorescence microscope. It is very difficult to clone a GFP-fused protein into its native location in the genome without affecting expression levels, so this method often cannot be used to measure endogenous gene expression. It is, however, widely used to measure the expression of a gene artificially introduced into the cell, for example via an expression vector. By fusing a target protein to a fluorescent reporter, the protein's behavior, including its cellular localization and expression level, can be significantly changed. The enzyme-linked immunosorbent assay works by using antibodies immobilised on a microtiter plate to capture proteins of interest from samples added to the well. Using a detection antibody conjugated to an enzyme or fluorophore the quantity of bound protein can be accurately measured by fluorometric or colourimetric detection. The detection process is very similar to that of a Western blot, but by avoiding the gel steps more accurate quantification can be achieved.
=== Phase separation revisited === Advances in confocal microscopy at the end of the 20th century identified proteins, RNA or carbohydrates localising to many non-membrane bound cellular compartments within the cytoplasm or nucleus which were variously referred to as 'puncta/dots', 'signalosomes', 'granules', 'bodies', 'assemblies', 'paraspeckles', 'purinosomes', 'inclusions', 'aggregates' or 'factories'. During this time period (1995-2008) the concept of phase separation was re-borrowed from colloidal chemistry & polymer physics and proposed to underlie both cytoplasmic and nuclear compartmentalization. Since 2009, further evidence for biomacromolecules undergoing intracellular phase transitions (phase separation) has been observed in many different contexts, both within cells and in reconstituted in vitro experiments. The newly coined term "biomolecular condensate" refers to biological polymers (as opposed to synthetic polymers) that undergo self assembly via clustering to increase the local concentration of the assembling components, and is analogous to the physical definition of condensation. In physics, condensation typically refers to a gas–liquid phase transition.
=== Differential display analysis === Also, a differential display analysis conducted in an erythroleukaemia cell line by Lin and co-researchers discovered that PIDD1 is a direct transcriptional target of p53. Furthermore, PIDD1 overexpression inhibited cell growth by triggering apoptosis in p53-deficient cells, an effect that was reversed when PIDD1 was knocked down. This led to the assumption that PIDD1 plays a critical role in the apoptotic pathway regulated by p53. In p53-deficient HCT116 and HEK293 cells which express the large T antigen, a basal level of PIDD1 expression was observed. This finding suggests that PIDD1 may play roles beyond its traditional involvement in the p53-mediated DNA damage response.
Sources: en.wikipedia.org
Sivasankar and his research team have found that the mechanism behind the puzzling phenomenon is due to long-lived, force-induced hydrogen bonds. Using data from previous experiments, the team used molecular dynamics to discover that two rod-shaped cadherins in an X-dimer formed catch bonds when pulled and in the presence of calcium ions. The calcium ions keep the cadherins rigid, while pulling brings the proteins closer together, allowing for hydrogen bonds to form. The mechanism behind catch bonds helps to explain the biophysics behind cell-cell adhesion. According to the researchers, "Robust cadherin adhesion is essential for maintaining the integrity of tissue such as the skin, blood vessels, cartilage and muscle that are exposed to continuous mechanical assault." The above catch bonds are formed between adhesion receptors and ligands, and among structural molecules and motor proteins, which bear force or generate force in their physiological function. An interesting recent development is the discoveries of catch bonds formed between signaling receptors and their ligands. These include bonds between T cell antigen receptors (TCR) or pre-TCR and peptide presented by major histocompatibility complex (pMHC) molecules, Fc gamma receptor and IgG Fc, and notch receptor and ligands. The presence of catch bonds in the interactions of these signaling (rather than adhesion) receptors have been suggested to be indicative of a possible role of these receptors as mechanoreceptors.
=== Regulation by keap1/nrf2/are pathway === External (via chemicals) and internal (stress response or caloric restriction) induction of NQO1 is mediated solely through the Keap1/Nrf2/ARE. Keap1 acts as the sensor which loses its ability to target Nrf2 for degradation upon exposure to the inducers. Nrf2 is consequently stabilized and accumulated in the nucleus upon which it binds to the AREs and initiates expression of cytoprotective genes including NQO1.
=== Dispersion in the environment === After production in the upper atmosphere, the carbon-14 reacts rapidly to form mostly (about 93%) 14CO (carbon monoxide), which subsequently oxidizes at a slower rate to form 14CO2, radioactive carbon dioxide. The gas mixes rapidly and becomes evenly distributed throughout the atmosphere (the mixing timescale on the order of weeks). Carbon dioxide also dissolves in water and thus permeates the oceans, but at a slower rate. The atmospheric half-life for removal of 14CO2 has been estimated at roughly 12 to 16 years in the Northern Hemisphere. The transfer between the ocean shallow layer and the large reservoir of bicarbonates in the ocean depths occurs at a limited rate. In 2009 the activity of 14C was 238 Bq per kg carbon of fresh terrestrial biomatter, close to the values before atmospheric nuclear testing (226 Bq/kg C; 1950).
=== Thorium-229 === 229Th is a radioactive isotope of thorium that decays by alpha emission with a half-life of 7916 years. 229Th is produced by the decay of uranium-233, and its principal use is for the production of the medical isotopes actinium-225 and bismuth-213.
== Nixon administration == The war on drugs was declared by President Richard Nixon during a special message to Congress delivered on June 17, 1971, in response to increasing rates of death from narcotics. During his announcement, Nixon mentioned fighting the war on two fronts: the supply front and the demand front. To address the supply front, Nixon requested funding to train narcotics officers internationally and proposed various legislation to disrupt manufacturers of illegal drugs. The demand front referred to enforcement and rehabilitation; Nixon proposed the creation of the Special Action Office of Drug Abuse Prevention to co-ordinate various agencies in addressing demand for illegal drugs. The mission of President Nixon and the United States government was to use the war on drugs to emphasize law enforcement, reduce the supply of illicit drugs, arresting distributors, and attempting to prove a lesson to the people of America to stop using and selling drugs. Although, this drifted towards a focus on minorities. Prisons were filled with individuals arrested for nonviolent drug offenses, and most of the prisoners were a minority in the United States. He also requested an additional $155 million for treatment and rehabilitation programs and additional funding to increase the size and technological capability of the Bureau of Narcotics and Dangerous Drugs.
Sources: en.wikipedia.org
== Second Ministry == On 22 February 2001, following the 2001 election, a ministry of 19 cabinet ministers and 5 parliamentary secretaries was sworn in. It served until the reconstitution of the Ministry on 12 February 2004 following the 2004 election.
===== Nanocubes ===== Silver nanocubes can be synthesized using ethylene glycol as a reducing agent and PVP as a capping agent, in a polyol synthesis reaction (vide supra). A typical synthesis using these reagents involves adding fresh silver nitrate and PVP to a solution of ethylene glycol heated at 140 °C. This procedure can actually be modified to produce another anisotropic silver nanostructure, nanowires, by just allowing the silver nitrate solution to age before using it in the synthesis. By allowing the silver nitrate solution to age, the initial nanostructure formed during the synthesis is slightly different than that obtained with fresh silver nitrate, which influences the growth process, and therefore, the morphology of the final product. Nanorods, Nanobars, and Nanowires Silver nanorods (also categorized as nanobars or nanowires depending on their aspect ratio), are a class of anisotropic nanoparticles extensively studied for their tunable electrical and optical properties. Their morphology is typically controlled by selective capping agents during the synthesis. For instance, polyvinylpyrrodine (PVP) can strongly bind to the {100} facets of silver seeds while interacting more weakly with the {111} facets. This preferential adsorption restricts growth on the {100} surfaces and promotes elongation at the <110> direction, ultimately resulting in the formation of rod-like structures.
=== EC 1.14.21 With NADH or NADPH as one donor, and the other dehydrogenated === EC 1.14.21.1: Now EC 1.14.19.64, (S)-stylopine synthase EC 1.14.21.2: Now EC 1.14.19.65, (S)-cheilanthifoline synthase EC 1.14.21.3: Now EC 1.14.19.66, berbamunine synthase EC 1.14.21.4: Now EC 1.14.19.67, salutaridine synthase EC 1.14.21.5: Now EC 1.14.19.68, (S)-canadine synthase EC 1.14.21.6: Now EC 1.14.19.20, Δ7-sterol 5(6)-desaturase EC 1.14.21.7: Now EC 1.14.19.69, biflaviolin synthase EC 1.14.21.8: Now EC 1.14.19.63, pseudobaptigenin synthase EC 1.14.21.9: Now EC 1.14.19.70, mycocyclosin synthase * EC 1.14.21.10: Now EC 1.14.19.71, fumitremorgin C synthase * EC 1.14.21.11: Now EC 1.14.19.72, (–)-pluviatolide synthase * EC 1.14.21.12: Now EC 1.14.19.73, (S)-nandinine synthase *
=== Infection === The 'danger area of the scalp' is the area of loose connective tissue. This is because pus and blood spread easily within it, and can pass into the cranial cavity along the emissary veins. Therefore, infection can spread from the scalp to the meninges, which could lead to meningitis.further studies are needed to conclude that it’s actually a “danger zone” though.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.